Results of the DSA for the number of diagnosed VP cases. by Benjamin Ruban-Fell (10791208)

Docking results of effective compounds in TFDM. by Xu Hu (23350)

“…</p><p>Results</p><p>21 active components were screened, 158 potential drug targets for the prevention and treatment of CIRI were obtained, 53 main targets were further screened in the protein-protein interaction network, and 106 signal pathways, 76 biological processes, 26 cell components and 50 molecular functions were enriched (P<0.05). Through the compound-target-pathway network, the key compounds that play a role in the prevention and treatment of CIRI, such as acacetin, apigenin and other flavonoids, as well as the corresponding key targets and key signal pathways, such as AKT1, SRC and EGFR were obtained. …”

Active compounds screened from TFDM. by Xu Hu (23350)

“…</p><p>Results</p><p>21 active components were screened, 158 potential drug targets for the prevention and treatment of CIRI were obtained, 53 main targets were further screened in the protein-protein interaction network, and 106 signal pathways, 76 biological processes, 26 cell components and 50 molecular functions were enriched (P<0.05). Through the compound-target-pathway network, the key compounds that play a role in the prevention and treatment of CIRI, such as acacetin, apigenin and other flavonoids, as well as the corresponding key targets and key signal pathways, such as AKT1, SRC and EGFR were obtained. …”

Network of compound-target-pathway. by Xu Hu (23350)

“…</p><p>Results</p><p>21 active components were screened, 158 potential drug targets for the prevention and treatment of CIRI were obtained, 53 main targets were further screened in the protein-protein interaction network, and 106 signal pathways, 76 biological processes, 26 cell components and 50 molecular functions were enriched (P<0.05). Through the compound-target-pathway network, the key compounds that play a role in the prevention and treatment of CIRI, such as acacetin, apigenin and other flavonoids, as well as the corresponding key targets and key signal pathways, such as AKT1, SRC and EGFR were obtained. …”

ERDRP-0519 potently inhibits <i>de novo</i> RNA synthesis. by Robert M. Cox (8029568)

“…<p><b>A-F)</b> Purified recombinant WT MeV L-P complexes or complexes harboring the L_T776A or L_H589Y resistance mutations were incubated with either a 16-nt RNA template (A) and the represented NTPs to assess <i>de novo</i> RNA synthesis or a 16-nt RNA template (B), a 5’-phosphorylated 4-nt primer, and the represented NTPs to assess primer extension. …”

Results of the PSA for the difference versus no screening (number of referrals to TVS and number of diagnosed VP cases). by Benjamin Ruban-Fell (10791208)

Species richness of birds along a rainforest elevational gradient in New Britain, Papua New Guinea by Katerina Sam (2561860)

Branching behavior of a N = 10 units network at Trial T (case of strong inhibition = 0.60) by Elif Köksal-Ersöz (20378631)

“…For a medium punishment (50% decrease in gain), this ratio decreases to 1%. …”

Image_3_CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.tif by Chenhui Cai (11475433)

Image_2_CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.tif by Chenhui Cai (11475433)

Table_1_CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.docx by Chenhui Cai (11475433)

Image_1_CDT1 Is a Novel Prognostic and Predictive Biomarkers for Hepatocellular Carcinoma.tif by Chenhui Cai (11475433)

PEA performed for different durations of incubation after the dilution step, for three concentrations of rPCT. by Frederic Bedin (3402254)

“…<p>The incubation time after dilution of the binding product was progressively decreased from 5 min (reference test, ref.) down to 30 sec. …”

PEA performed for different durations of antigen/antibody binding, for three concentrations of rPCT. by Frederic Bedin (3402254)

“…<p>The time of incubation between the rPCT and the PEA probes was progressively decreased from 1h (reference test, ref.) down to 5 minutes. …”

Clinical effectiveness and cost-effectiveness as a function of PrEP adherence, HIV prevalence and behavioral disinhibition. by Anders Chen (640309)

Serum lipoxin A4 (LXA4) and resolvin D1 (RvD1) deficiency in patients with sleep-disordered breathing. by Yung-Che Chen (381913)

“…<p>(A) Serum RvD1 and (B) LXA4 levels were both decreased in patients with primary snoring (PS), treatment-naïve OSA, and severe OSA on CPAP treatment as compared with that in the healthy subjects (HS). …”

Mapping the properties of cells in relation to their local neighborhood. by Matthew French (13007466)

“…<b>D:</b> Heightened TBXT and TBX6 CV to the NMP region and decreases into the mesodermal PS. Lines indicate the fit of a non-parametric multiple regression curve and shading indicates 0.05 and 0.95 confidence intervals calculated as (mean ± 1.96 * (<i>σ</i>/(√<i>n</i>)). …”

Involvement of the BMP pathway. by Pascale Plaisancié (13531638)

Debt maturity, financial crisis and corporate performance in GCC countries: A dynamic-GMM approach by Zeitun, Rami

Get full text
Get full text
Get full text

Population impact of lung cancer screening in the United States: Projections from a microsimulation model by Steven D. Criss (3821332)

“…</p><p>Methods/Findings</p><p>Utilizing a well-validated microsimulation model, we estimated the benefits and harms of an annual low-dose computed tomography screening scenario with a realistic screening adherence rate versus a no-screening scenario for the US population from 2016–2030. …”